Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
AstraZeneca / Daiichi Sankyo Enhertu Redefines First-Line HER2+ Metastatic Breast Cancer Care Enhertu (trastuzumab deruxtecan), an antibodydrug conjugate, became the first ADC approved for first-line treatment of HER2-positive metastatic breast cancer after delivering a marked improvement in progression-free survival versus the long-standing THP standard in the Phase III DESTINY-Breast09 trial
At the policy level, extended producer responsibility (EPR) schemes can hold pharmaceutical manufacturers accountable for the entire lifecycle of their products
doi:10.1002/nbm.966
A clear, vibrant solution is a sign of a healthy compound
Listen to your bodys signals
It was found that Alzheimers patients that were randomly assigned to the acetyl l-carnitine group (ingesting 2.5-3g daily) again had a slower rate of deterioration in a range of neuropsychological parameters
